Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
A Firefly is lighting up operating rooms, making it easier for robotic surgeons to remove tumors. However, this Firefly is not the type that children catch in a jar during warm summer evenings. Instead, it’s a technology that uses a wavelength of light not visible to the human eye. A special dye is then injected which causes a bright green fluorescence of certain tissues, hence the name “Firefly.” This green glow lets surgeons clearly see the difference between cancerous and healthy tissue when performing surgery, allowing them to remove the tumor while saving the rest of the healthy organ.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342452-firefly-lighting-operating-rooms/
John Peden was one of those larger-than-life personalities. “When he would walk into a room, it was like all the attention was on him,” said his stepdaughter, Jenna Peden. “He just had this power emanating out of him.”
The 6-foot, 4-inch former U.S. Air Force captain was a respected dental surgeon in Nashville. He was active in his church and made many mission trips to provide dental care in Central America through Health Talents International.
That’s why it was such a shock to his family and friends when an MRI revealed a brain tumor the size of a golf ball. “Life as we knew it was no more,” said his wife, Vicki Peden. “John never worked another day in his life.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7100754-northwestern-mutual-client-stories-planning-preparation-pay-off/
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
It was January 2012, Isaac dribbled the ball; shot it through the hoop, swish! This was a simple moment the 15-year-old athlete who once participated in cross country, soccer and basketball, thought he’d never experience again. Ten months earlier, Isaac was diagnosed with a brain tumor. He became a patient at St. Jude Children’s Research Hospital® and through extensive treatment and care, his cancer is in remission and he is able to play the sports he loves.
Chili’s® Grill & Bar is helping St. Jude patients like Isaac enjoy their own special, everyday moments through the brand’s ninth annual Create-A-Pepper to Fight Childhood Cancer campaign. Participating Chili’s restaurants nationwide and in Puerto Rico are joining in the fight against childhood cancer and other life-threatening diseases. September is National Childhood Cancer Awareness month and through Sept. 26, Chili’s guests can help the cause by donating at their local restaurants and online.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57540-chili-s-create-a-pepper-for-st-jude
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
Dr. Samuel Aguiar Jr. - Hospital do Câncer - AC CamargoMédico do Departamento de Cirurgia Pélvicahttp://184.108.40.206/index.php?option=com_content&task=view&id=29&Itemid=33
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma